Edition:
United Kingdom

Shionogi & Co Ltd (4507.T)

4507.T on Tokyo Stock Exchange

6,220JPY
1:48am BST
Change (% chg)

¥-11 (-0.18%)
Prev Close
¥6,231
Open
¥6,177
Day's High
¥6,220
Day's Low
¥6,123
Volume
150,800
Avg. Vol
1,041,866
52-wk High
¥7,796
52-wk Low
¥5,639

About

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company, mainly engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The Company mainly provides its products and services in Japan, Europe and North America markets.

Overall

Beta: 0.92
Market Cap(Mil.): ¥1,973,895.00
Shares Outstanding(Mil.): 316.79
Dividend: 50.00
Yield (%): 1.51

Financials

  4507.T Industry Sector
P/E (TTM): 14.79 30.63 34.52
EPS (TTM): 421.24 -- --
ROI: 20.19 13.02 12.69
ROE: 20.92 14.18 17.17

As steep patent cliff looms, Shionogi moves to develop its own U.S. sales staff

TOKYO For much of its 141-year history, Japan's Shionogi & Co Ltd has played safe when selling its drugs in the United States and other overseas markets - relying on bigger partners to promote its products and avoiding the cost of maintaining a large sales force.

17 Jul 2019

As steep patent cliff looms, Shionogi moves to develop its own U.S. sales staff

TOKYO For much of its 141-year history, Japan's Shionogi & Co Ltd has played safe when selling its drugs in the United States and other overseas markets - relying on bigger partners to promote its products and avoiding the cost of maintaining a large sales force.

17 Jul 2019

FOCUS-As steep patent cliff looms, Shionogi moves to develop its own U.S. sales staff

TOKYO, July 17 For much of its 141-year history, Japan's Shionogi & Co Ltd has played safe when selling its drugs in the United States and other overseas markets - relying on bigger partners to promote its products and avoiding the cost of maintaining a large sales force.

17 Jul 2019

Japanese drugmaker Shionogi sees record profit on royalty income

TOKYO Japanese drugmaker Shionogi & Co Ltd forecast a 6.1 percent jump in full-year operating profit to what would be its fifth straight record high, underpinned by strong royalty income from its HIV drugs.

09 May 2019

UPDATE 1-Japanese drugmaker Shionogi sees record profit on royalty income

* Annual profit forecast to rise 6.1 pct to record 147 bln yen

09 May 2019

Japanese drugmaker Shionogi sees profit rising on royalty income

TOKYO, May 9 Japanese drugmaker Shionogi & Co Ltd expects its annual operating profit to rise 6.1 percent, it said on Thursday, underpinned by strong royalty income from its HIV drugs.

09 May 2019

RPT-BRIEF-Shionogi & Co Ltd Announces Agreements On Collaborative Research With Peptidream For New Peptide Drug Conjugate(Pdc) Discovery

* SHIONOGI & CO LTD ANNOUNCES AGREEMENTS ON COLLABORATIVE RESEARCH WITH PEPTIDREAM INC FOR NEW PEPTIDE DRUG CONJUGATE (PDC) DISCOVERY Source text for Eikon: Further company coverage:

23 Jan 2019

Earnings vs. Estimates